<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04425018</url>
  </required_header>
  <id_info>
    <org_study_id>20-068</org_study_id>
    <nct_id>NCT04425018</nct_id>
  </id_info>
  <brief_title>MARGetuximab Or Trastuzumab (MARGOT)</brief_title>
  <acronym>MARGOT</acronym>
  <official_title>MARGetuximab Or Trastuzumab (MARGOT): A Phase II Study Comparing Neoadjuvant Paclitaxel/Margetuximab/Pertuzumab to Paclitaxel/Trastuzumab/Pertuzumab in Patients With Stage II-III HER2-positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MacroGenics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Translational Breast Cancer Research Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine how well participants with stage II-III&#xD;
      HER2-positive breast cancer respond to pre-operative treatment using one of two different&#xD;
      combinations of drugs.&#xD;
&#xD;
      Drugs and Combinations used:&#xD;
&#xD;
        -  Paclitaxel, Pertzumab and Margetuximab (Margenza)&#xD;
&#xD;
        -  Paclitaxel, Pertzumab and Trastuzumab (Herceptin)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized open-label phase II trial comparing paclitaxel/margetuximab/pertuzumab&#xD;
      (TMP) to paclitaxel/trastuzumab/pertuzumab (THP) in patients with anatomic stage II-III HER2&#xD;
      positive breast cancer.&#xD;
&#xD;
        -  The research study procedures include screening for eligibility and study treatment&#xD;
           including laboratory evaluations, two mandatory research biopsies and follow up visits.&#xD;
&#xD;
        -  Participants will be randomized, which means randomly assigned, to one of two treatment&#xD;
           arms. The treatment arms in this study and the names of the study drugs in each arm are:&#xD;
&#xD;
             -  Arm A: Paclitaxel, Pertzumab and Margetuximab&#xD;
&#xD;
             -  Arm B: Paclitaxel, Pertzumab and Trastuzumab&#xD;
&#xD;
      Participants will receive study treatment for 12 weeks prior to surgery and will be followed&#xD;
      for 10 years after surgery. After surgery, some participants will continue to receive the&#xD;
      study drug margetuximab for a year in total, if they respond very well to the first 12 weeks&#xD;
      of treatment with margetuximab.&#xD;
&#xD;
      It is expected that about 171 people will take part in this research study.&#xD;
&#xD;
      This research study is a Phase II clinical trial. Phase II clinical trials test the safety&#xD;
      and effectiveness of an investigational drug combination to learn whether the drug&#xD;
      combination works in treating a specific disease. &quot;Investigational&quot; means that the drug&#xD;
      combination is being studied.&#xD;
&#xD;
      The FDA (the U.S. Food and Drug Administration) has approved paclitaxel, trastuzumab&#xD;
      (Herceptin), and pertuzumab as part of a pre-operative treatment option for stage II-III&#xD;
      HER2-positive breast cancer.&#xD;
&#xD;
      The U.S. Food and Drug Administration (FDA) has approved margetuximab (Margenza) for advanced&#xD;
      HER2-positive breast cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 13, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of pathologic complete response (pCR)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Compare rate of pathologic complete response (pCR, defined as RCB 0) in patients with the FF or FV CD16A genotype and anatomic stage II-III HER2+ breast cancer treated with 4 cycles of neoadjuvant TMP or THP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of pathologic complete response</measure>
    <time_frame>12 weeks</time_frame>
    <description>Compare rate of pCR (RCB 0) in patients treated with TMP or THP, according to hormone receptor-positive (HR+) or hormone receptor-negative (HR-) status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual Cancer Burden (RCB) scores</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assess Residual Cancer Burden (RCB) scores1 in patients treated with TMP or THP, overall and according to HR+ or HR- status. reported using the Residual Cancer Burden calculator from M.D Anderson:</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic response rate</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Assess radiographic response to neoadjuvant therapy in patients treated with TMP or&#xD;
THP, overall and according to HR+ or HR- status.Response criteria are based on the RECIST 1.1 criteria:</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Treatment Related Adverse Events according to CTCAE v5.0</measure>
    <time_frame>From first treatment to 12 weeks</time_frame>
    <description>Assessment of DLTs on Arm A during the first 21 days of treatment Maximum grade of all treatment-related adverse events according to CTCAE v5.0 Patient-reported outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival rate (EFS)</measure>
    <time_frame>From enrollment to occurrence invasive local/regional recurrence distant recurrence or death from breast cancer or up to 10 years</time_frame>
    <description>The distribution of the survival function and cumulative incidence function for EFS, summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival rate (EFS) Patients with RCB 0 or 1</measure>
    <time_frame>From enrollment to occurrence of invasive local/regional recurrence distant recurrence or death from breast cancer or up to 10 years</time_frame>
    <description>The distribution of the survival function and cumulative incidence function for EFS, summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival rate (EFS)Patients with RCB 2 or 3</measure>
    <time_frame>From enrollment to occurrence of invasive local/regional recurrence distant recurrence or death from breast cancer or up to 10 years</time_frame>
    <description>The distribution of the survival function and cumulative incidence function for EFS, summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival rate (EFS) Patients randomized to neoadjuvant TMP</measure>
    <time_frame>From enrollment to occurrence of invasive local/regional recurrence distant recurrence or death from breast cancer or up to 10 years</time_frame>
    <description>The distribution of the survival function and cumulative incidence function for EFS, summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival rate (EFS) patients randomized to neoadjuvant THP</measure>
    <time_frame>From enrollment to occurrence of invasive local/regional recurrence distant recurrence or death from breast cancer or up to 10 years</time_frame>
    <description>The distribution of the survival function and cumulative incidence function for EFS, summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival rate (EFS) -Patients with pCR</measure>
    <time_frame>From enrollment to occurrence of invasive local/regional recurrence distant recurrence or death from breast cancer or up to 10 years</time_frame>
    <description>The distribution of the survival function and cumulative incidence function for EFS, summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival rate (EFS) -Patients without pCR</measure>
    <time_frame>From enrollment to occurrence of invasive local/regional recurrence distant recurrence or death from breast cancer or up to 10 years</time_frame>
    <description>The distribution of the survival function and cumulative incidence function for EFS, summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free interval rate (RFI)</measure>
    <time_frame>patients who undergo surgery for breast cancer as the interval from the time of surgery until the occurrence of invasive local/regional recurrence distant recurrence or death from breast cancer or up to 10 years</time_frame>
    <description>The distribution of the survival function and cumulative incidence function for RFI summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free interval rate (RFI) RCB 0 or 1</measure>
    <time_frame>patients who undergo surgery for breast cancer as the interval from the time of surgery until the occurrence of invasive local/regional recurrence distant recurrence or death from breast cancer or up to 10 years</time_frame>
    <description>The distribution of the survival function and cumulative incidence function for RFI summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free interval rate (RFI) RCB 2 or 3</measure>
    <time_frame>patients who undergo surgery for breast cancer as the interval from the time of surgery until the occurrence of invasive local/regional recurrence distant recurrence or death from breast cancer or up to 10 years</time_frame>
    <description>The distribution of the survival function and cumulative incidence function for RFI summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free interval rate (RFI) Patients randomized to neoadjuvant TMP</measure>
    <time_frame>patients who undergo surgery for breast cancer as the interval from the time of surgery until the occurrence of invasive local/regional recurrence distant recurrence or death from breast cancer or up to 10 years</time_frame>
    <description>The distribution of the survival function and cumulative incidence function for RFI summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free interval rate (RFI) Patients randomized to neoadjuvant THP</measure>
    <time_frame>patients who undergo surgery for breast cancer as the interval from the time of surgery until the occurrence of invasive local/regional recurrence distant recurrence or death from breast cancer or up to 10 years</time_frame>
    <description>The distribution of the survival function and cumulative incidence function for RFI summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free interval rate (RFI) Patients with pCR</measure>
    <time_frame>patients who undergo surgery for breast cancer as the interval from the time of surgery until the occurrence of invasive local/regional recurrence distant recurrence ror death from breast cancer or up to 10 years</time_frame>
    <description>The distribution of the survival function and cumulative incidence function for RFI summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free interval rate (RFI) Patients without pCR</measure>
    <time_frame>patients who undergo surgery for breast cancer as the interval from the time of surgery until the occurrence of invasive local/regional recurrence distant recurrence or death from breast cancer or up to 10 years</time_frame>
    <description>The distribution of the survival function and cumulative incidence function for RFI summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival Rate (OS)</measure>
    <time_frame>up to 10 years from definitive surgery.</time_frame>
    <description>The distribution of the survival function and cumulative incidence function for OS, summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival Rate (OS) Patients with RCB 0 or 1</measure>
    <time_frame>up to 10 years from definitive surgery.</time_frame>
    <description>The distribution of the survival function and cumulative incidence function for OS, summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival Rate (OS) Patients with RCB 2 or 3</measure>
    <time_frame>up to 10 years from definitive surgery.</time_frame>
    <description>The distribution of the survival function and cumulative incidence function for OS, summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival Rate (OS) Patients randomized to neoadjuvant TMP</measure>
    <time_frame>up to 10 years from definitive surgery.</time_frame>
    <description>The distribution of the survival function and cumulative incidence function for OS, summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival Rate (OS) randomized to neoadjuvant THP</measure>
    <time_frame>up to 10 years from definitive surgery.</time_frame>
    <description>The distribution of the survival function and cumulative incidence function for OS, summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival Rate (OS) Patients with pCR</measure>
    <time_frame>up to 10 years from definitive surgery.</time_frame>
    <description>The distribution of the survival function and cumulative incidence function for OS, summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival Rate (OS) Patients without CR</measure>
    <time_frame>up to 10 years from definitive surgery.</time_frame>
    <description>The distribution of the survival function and cumulative incidence function for OS, summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">171</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Stage II Breast Cancer</condition>
  <condition>Stage III Breast Cancer</condition>
  <condition>HER2-positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Paclitaxel + Pertuzumab + Margetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The research study procedures include screening for eligibility and study treatment including laboratory evaluations, two mandatory research biopsies and follow up visits.Cycle=21 days&#xD;
Paclitaxel- via IV, Day 1,8,15 of each cycle&#xD;
Margetuximab via IV, Day 1 of each cycle&#xD;
Pertuzumab via IV, Day 1 of each cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel + Pertuzumab + Trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The research study procedures include screening for eligibility and study treatment including laboratory evaluations, two mandatory research biopsies and follow up visits.Cycle=21 days&#xD;
Paclitaxel- via IV, Day 1,8,15 of each cycle&#xD;
Pertuzumab via IV, Day 1 of each cycle&#xD;
Trastuzumab via IV, Day 1 of each cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Pre-determined dose administered via IV, Day 1,8,15 of each cycle 4 study cycles, or 12 weeks.</description>
    <arm_group_label>Paclitaxel + Pertuzumab + Margetuximab</arm_group_label>
    <arm_group_label>Paclitaxel + Pertuzumab + Trastuzumab</arm_group_label>
    <other_name>Taxol</other_name>
    <other_name>Onxal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pertuzumab</intervention_name>
    <description>Pre-determined dose administered via IV - Day 1 of each 21- day cycle 4 study cycles, or 12 weeks.</description>
    <arm_group_label>Paclitaxel + Pertuzumab + Margetuximab</arm_group_label>
    <arm_group_label>Paclitaxel + Pertuzumab + Trastuzumab</arm_group_label>
    <other_name>Perjeta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Margetuximab</intervention_name>
    <description>Pre-determined dose administered by IV - Day 1 of each 21- day cycle 4 study cycles, or 12 weeks.</description>
    <arm_group_label>Paclitaxel + Pertuzumab + Margetuximab</arm_group_label>
    <other_name>Margenza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Pre-determined dose administered via IV Day 1 of each 21- day cycle for 4 study cycles, or 12 weeks.</description>
    <arm_group_label>Paclitaxel + Pertuzumab + Trastuzumab</arm_group_label>
    <other_name>Herceptin</other_name>
    <other_name>Kanjinti</other_name>
    <other_name>Ogivri</other_name>
    <other_name>Herzuma</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Stage II or III (according to AJCC cancer staging manual anatomic staging table, 8th&#xD;
             edition) histologically confirmed invasive carcinoma of the breast. A minimum tumor&#xD;
             size of 1.5 cm (in breast mass or axillary lymph node) determined by physical exam or&#xD;
             imaging (whichever is larger) is required. Patients with inflammatory breast carcinoma&#xD;
             (T4d) are NOT eligible.&#xD;
&#xD;
          -  Centrally confirmed to have a low affinity CD16 germline genotype (FF or FV)&#xD;
&#xD;
          -  HER-2 positive by 2018 American Society of Clinical Oncology/College of American&#xD;
             Pathologists criteria, as assessed by standard institutional guidelines (central&#xD;
             testing is not required).&#xD;
&#xD;
          -  ER/PR determination is required. ER- and PR-assays should be performed by&#xD;
             immunohistochemical methods according to standard institutional guidelines&#xD;
&#xD;
          -  Bilateral breast cancers are allowed as long as both cancers are HER2-positive (as&#xD;
             defined in 3.1.2), or the contralateral cancer is a &lt;1 cm, ER+ tumor.&#xD;
&#xD;
          -  Patients with multifocal or multicentric disease are eligible if the treating&#xD;
             investigator hasdetermined the patient should be treated as HER2-positive.&#xD;
&#xD;
          -  Breast imaging should include dedicated ultrasound of the ipsilateral axilla. For&#xD;
             subjects with a clinically positive axilla based on exam or imaging, a fine needle&#xD;
             aspiration or core biopsy procedure will be performed to determine the presence of&#xD;
             metastatic disease in the lymph nodes (though lymph node sampling procedure need not&#xD;
             be resulted prior to patient's registration on trial, as long as all other eligibility&#xD;
             are met).&#xD;
&#xD;
          -  Men and women (with any menopausal status) ≥18 years of age are eligible.&#xD;
&#xD;
          -  ECOG performance status 0 or 1&#xD;
&#xD;
          -  Required laboratory values demonstrating adequate organ function:&#xD;
&#xD;
               -  ANC ≥ 1000/mm3&#xD;
&#xD;
               -  Hemoglobin ≥ 9 g/dl&#xD;
&#xD;
               -  Platelets ≥ 100,000/mm3&#xD;
&#xD;
               -  Serum creatinine &lt; 1.5 x ULN (institutional) OR calculated GFR ≥ 60mL/min&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 x ULN (institutional). For patients with Gilbert Syndrome,&#xD;
                  the direct bilirubin should be within the institutional normal range OR total&#xD;
                  bilirubin ≤ 2.0 mg/dL.&#xD;
&#xD;
               -  AST and ALT ≤ 2.5x ULN (institutional) Left ventricular ejection fraction (LVEF)&#xD;
                  ≥ 50%.&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum pregnancy test within 14&#xD;
             days of treatment start. Childbearing potential is defined as: those who have not been&#xD;
             surgically sterilized and/or have had a menstrual period in the past 12 months&#xD;
&#xD;
          -  Women of childbearing potential and men with partners of childbearing potential must&#xD;
             be willing to use one highly effective form of non-hormonal contraception or two&#xD;
             effective forms of non-hormonal contraception by the patient and/or partner and&#xD;
             continue its use for the duration of the study treatment and for 7 months after the&#xD;
             last dose of study treatment.&#xD;
&#xD;
          -  Patients with a history of ipsilateral or contralateral DCIS or LCIS are eligible.&#xD;
&#xD;
          -  Patients undergoing breast conservation therapy (i.e. lumpectomy) must not have any&#xD;
             contraindications to radiation therapy.&#xD;
&#xD;
          -  Non-English-speaking patients are eligible but will be exempt from patient-completed&#xD;
             questionnaires.&#xD;
&#xD;
          -  Willing and able to sign informed consent.&#xD;
&#xD;
          -  Willing to undergo breast biopsy for research purposes.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or nursing women due to the teratogenic potential of the study drugs.&#xD;
&#xD;
          -  Active, unresolved infection requiring intervention&#xD;
&#xD;
          -  Receipt of intravenous antibiotics for infection within 7 days prior to registration.&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic &gt;180 mm Hg and/or diastolic &gt;100 mm Hg) or&#xD;
             clinically significant (i.e. active) cardiovascular disease: cerebrovascular&#xD;
             accident/stroke or myocardial infarction within 6 months prior to first study&#xD;
             medication, unstable angina, congestive heart failure (CHF) of New York Heart&#xD;
             Association (NYHA) Class II or higher, or serious cardiac arrhythmia requiring&#xD;
             medication.&#xD;
&#xD;
          -  Significant symptoms (Grade ≥ 2) from peripheral neuropathy.&#xD;
&#xD;
          -  Other concurrent serious diseases that may interfere with planned treatment, including&#xD;
             severe pulmonary conditions/illness, uncontrolled infections, uncontrolled diabetes.&#xD;
&#xD;
          -  Any prior treatment for the current breast cancer, including chemotherapy, hormonal&#xD;
             therapy, radiation, or experimental therapy.&#xD;
&#xD;
          -  Patients with any prior history of invasive breast cancer within the past 5 years are&#xD;
             not eligible. Non-metastatic invasive breast cancers diagnosed more than 5 years ago&#xD;
             and any other type of prior non-metastatic cancer is allowed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian E Krop, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ian E Krop, MD, PHD</last_name>
    <phone>617-632-6973</phone>
    <email>Ian_Krop@dfci.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nellie Novielli</last_name>
      <email>noviella@georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Claudine Isaacs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy Malloy</last_name>
      <email>stacy.k.malloy@medstar.net</email>
    </contact>
    <investigator>
      <last_name>Claudine Isaacs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nana Peprah</last_name>
      <email>nowusu@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Rita Nanda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center at Silver Cross Hospital</name>
      <address>
        <city>New Lenox</city>
        <state>Illinois</state>
        <zip>60451</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>UChicago Cancer Clinical Trials</last_name>
      <phone>855-702-8222</phone>
      <email>cancerclinicaltrials@bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Rita Nanda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center for Advanced Care Orland Park</name>
      <address>
        <city>Orland Park</city>
        <state>Illinois</state>
        <zip>60462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>UChicago Cancer Clinical Trials</last_name>
      <phone>855-702-8222</phone>
      <email>cancerclinicaltrials@bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Rita Nanda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Krop, MD, PhD</last_name>
      <phone>617-632-6973</phone>
      <email>IKROP@PARTNERS.ORG</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana-Farber at Milford</name>
      <address>
        <city>Milford</city>
        <state>Massachusetts</state>
        <zip>01757</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Sinclair, MD</last_name>
      <email>NSINCLAIR1@PARTNERS.ORG</email>
    </contact>
    <investigator>
      <last_name>Natalie Sinclair, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber at South Shore Hospital</name>
      <address>
        <city>Weymouth</city>
        <state>Massachusetts</state>
        <zip>02190</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meredith Faggen, M.D.</last_name>
      <phone>781-624-4800</phone>
      <email>meredith_faggen@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Meredith Faggen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesus Anampa, MD</last_name>
      <email>janampa@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Jesus Anampa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crissey Tait</last_name>
      <email>crissey_tait@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Lisa Carey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rometa Pollard</last_name>
      <email>pollardrr@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Leisha Emens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Pavlick</last_name>
      <phone>713-798-7814</phone>
      <email>acpavlic@bcm.ed</email>
    </contact>
    <investigator>
      <last_name>Mothaffar Rimawi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenna Olyanich</last_name>
      <email>bolyanic@seattlecca.org</email>
    </contact>
    <investigator>
      <last_name>Rachel Yung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 15, 2020</study_first_submitted>
  <study_first_submitted_qc>June 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Adrienne G. Waks</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Stage II Breast Cancer</keyword>
  <keyword>Stage III Breast Cancer</keyword>
  <keyword>HER2-positive Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
    <mesh_term>Margetuximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Data can be shared no earlier than 1 year following the date of publication</ipd_time_frame>
    <ipd_access_criteria>Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

